ALBUQUERQUE, N.M., Jan. 24 /PRNewswire/ -- Exagen Diagnostics, Inc., which develops and commercializes genomic marker-based in vitro diagnostic (IVD) kits for prognosis and prediction of treatment response, today announced that Robert Mignatti has joined the company as president and COO. He oversees Exagen’s day-to-day operations, as well as company alliances. Exagen CEO Jim McClintic, who joined the company in October, will continue to guide the company’s strategic direction.
“Our mission is to focus innovative genomic and computational science on creating leading-edge markers and tests that individualize patient care worldwide,” said McClintic. “Bob’s expertise in business development and planning, strategic partnerships and acquisitions, and developing key personnel makes him a very strong asset as we build the management team that will elevate Exagen to its next phase of growth.”
Mignatti comes to Exagen with 33 years of laboratory and kit-based diagnostics experience, including senior management and sales roles at Esoterix, Inc., Allergy Testing Laboratory, Kallestad Diagnostics, Inc. and Baxter International. At Esoterix, which provides specialty value-added laboratory testing information services, Mignatti served as executive vice president and COO, working directly with McClintic for the past five years. Last year, McClintic and Mignatti led the sale of Esoterix to LabCorp, Inc. for $150 million.
“This is an exciting business opportunity because Exagen will be launching the first IVD kits to detect changes in DNA copy number in tumor tissue to predict risk of recurrence for both hormone receptor (HR)-positive and HR-negative breast cancer patients,” said Mignatti. “It’s also a privilege to help lead the commercialization of a scientific advancement that has the potential to significantly improve the quality of life for people with serious diseases.”
About Exagen Diagnostics, Inc.
As an emerging leader in the development of prognostic and predictive in vitro diagnostic (IVD) kits, Exagen Diagnostics is uniquely able to discover, validate and productize small sets of genomic markers for use in oncology, infectious disease and other indications. Exagen aims to commercialize IVD kits that can be performed by existing diagnostic laboratories and to develop tests that accompany the launch of new therapeutics and/or support pharmaceutical R&D/Phase IV. For more information, visit http://www.exagendiagnostics.com.
Exagen Diagnostics, Inc.
CONTACT: Ellen Mather, Director, Public Relations, Inc., +1-505-828-9093,emather@exagendiagnostics.com, of Exagen Diagnostics
Web site: http://www.exagendiagnostics.com/
